Efficacy and tolerability of Arnophyte cream for herpes infection, in subjects with early signs and symptoms of recurrent HSV-2

Kavita S. Salkar; Chetna S. Chotalia; Rajiv Y. Salvi; Nimesh D. Mehta; Anirudh T. Tripathi

doi:10.18203/issn.2455-4529.IntJResDermatol20194670

Authors

Kavita S. Salkar Department of Phytomedicines, Piramal Enterprises Limited, Mumbai, Maharashtra, India
Chetna S. Chotalia Department of Phytomedicines, Piramal Enterprises Limited, Mumbai, Maharashtra, India
Rajiv Y. Salvi Department of Phytomedicines, Piramal Enterprises Limited, Mumbai, Maharashtra, India
Nimesh D. Mehta Sai Medi Centre, Mumbai, Maharashtra, India
Anirudh T. Tripathi Life Veda Treatment and Research Centre, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20194670

Keywords:

Herpes, HSV, Clinical study, Anti-viral, Arnophyte cream, Ficus arnottiana

Abstract

Background: Arnophyte^® cream developed from Ficus arnottiana plant extract showed strong potential as an Anti-viral agent. The objective of the study was to evaluate the efficacy and tolerability of Arnophyte^® cream in subjects with early signs and symptoms of recurrent HSV-2.

Methods: The treatment was given for a period of 14 days. The study outcomes measured were assessment of reduction in pain using the visual analogue score (VAS), the changes in the quality of life index for recurrent genital herpes (GHQoLr); physician’s and patient’s global assessment of the therapy, signs and symptoms associated with HSV-2 and healing of the target lesion on baseline, day 2, day 4, day 7 and day 15.

Results: Arnophyte^® cream showed significant reduction in the signs and symptoms of herpes infection. The cream was well tolerated with no serious adverse events observed.

Conclusions: Arnophyte® cream can be considered as a possible therapeutic option for the treatment of recurrent herpes infections in both HSV-1 and HSV-2.

Metrics

Metrics Loading ...

References

Corey L. First episode, recurrent and asymptomatic herpes simplex infections. J Am Acad Dermatol. 1998;18:169-72.

Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;15;72(8):1527-34.

Muralidhar S, Talwar R, Kumar DA, Kumar J, Bala M, Khan N, et al. Genital Ulcer Disease: How Worrisome Is It Today? A Status Report from New Delhi, India. J Sexually Transmitted Dis. 2013:203636.

National Guidelines on Prevention, Management and Control of Reproductive Tract Infections Sexually Transmitted Infections. National AIDS Control Organization, Ministry of Health and Family Welfare. 2007:1Y70.

Corey L. Genital Herpes In: Holmes K, Mardh P-A, Sparling FP, Weisner PJ (eds). Sexually Transmitted Diseases. Chapter 35. New York: McGraw Hill Information Services Company; 1990.

Brugha R, Keersmaekers K, Renton A, Meheus A. Genital herpes infection: a review. Int J Epidemiol. 1997;26(4):698-709.

Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF. "Herpes simplex". Pediatr Rev. 2009;30(4):119-29.

Fleming DT, Mcquillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337:1105-11.

Smith JS, Robinson RJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1:a global review. J Infect Dis. 2002;186 (Suppl1):S3-28.

Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bulletin of the World Health Organization. 2008;86(10):805-12.

Corey L, Handsfield HH. Genital herpes and public health:addressing a global problem. JAMA. 2000;283(6):791-4.

Dhawan J, Khandpur S. Emerging trends in viral sexually transmitted infections in India. Indian J Dermatol Venereol Leprol. 2009;75:561-5.

Vibhu, M. Genital Herpes:Changing Pattern and Current Trends. Indian J Sex Transm Dis. 2006;27(1):6.

Becker M, Stephen J, Moses S, Washington R, Maclean I, Cheang M, et al. Etiology and determinants of sexually transmitted infections in Karnataka State, South India. Sex Transm Dis. 2009;36:1-6.

Kumar B, Sahoo B, Gupta S, Jain R. Rising incidence of genital herpes over two decades in a sexually transmitted disease clinic in north India. J Dermatol. 2002;29:74-8.

Ray K, Bala M, Gupta SM, Khunger N, Puri P, Muralidhar S, Kumar J. Changing trends in sexually transmitted infections at a Regional STD Centre in north India. Indian J Med Res. 2006;124:559-68.

Kaur R, Gupta N, Baveja UK. Seroprevalence of HSV1 and HSV2 infections in family planning clinic attenders. J Commun Dis. 2005;37(4):307-9.

Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sexually transmitted infections. 1999;1;75(6):398-402

Clercq ED, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology. 2006;147(1):1-11.

Clercq ED. Antiviral drugs in current clinical use. J Clin Virol. 2004;30:115-33.

Field HJ, Clercq ED. Antiviral drugs - a short history of their discovery and development. Microbiology Today. 2004;31:58-61.

Greco A, Diaz JJ, Thouvenot D & Morfin F. Novel targets for the development of anti - herpes compounds. Infectious Disorders - Drug Targets. 2007;7(1):11-8.

Kitazato K, Wang F, Kobayashi N. Viral infectious disease and natural products with antiviral activity, Drug Discovery Therapy. 2007;1(1):14-22.

Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003;66:206-20.

Chopra RN, Nayar SL, Chopra IC. Glossary of Indian Medicinal Plants, CSIR, New Dehli. 1996;ISBN:8172361262

Abonyi D, Adikwu MU, Esimone CO & Ibezim EC. Plants as sources of antiviral agents. African J Biotech. 2009;8:3989-94.

Le Cleach L, Trinquart L, Do G, Maruani A, Lebrun‐Vignes B, Ravaud P, Chosidow O. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database of Systematic Reviews 2014;8:CD009036.

Littler E, Oberg B. Achievements and challenges in antiviral drug discovery. Antiviral Chem Chemotherap. 2005;16:155-68.

Madhu V, Neena M. Antiviral drugs against herpes infections. Indian J Pharmacol. 2000;32:330-8.

Compare Herpes Drugs. Available at: https://www.herpes-coldsores.com/compare_ herpes_drugs.htm. Accessed on 3 June 2019.

Griffith RS, Norins AL, Kagan CA. Multicentered study of lysine therapy in Herpes simplex infection. Dermatologica. 1978;156:257-67.

Godfrey HR, Godfrey NJ, Godfrey JC, Riley D. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine. Altern Ther Health Med. 2001;7:49-56.

Lawrence RC, Hilton BL, Martin L. Topical Polyriboinosinic-Polyribocytidylic Acid Complex in the Treatment of Recurrent Genital Herpes. Antimicrobial Agents Chemotherap. 1982: 481-485.

Sacks SL, Portnoy J, Lawee D, Schlech W, Aoki FY, Tyrrell DL, et al. Clinical course of recurrent genital herpes and treatment with foscarnet cream:results of a Canadian multicenter trial. J Infect Dis. 1987;155(2):178-86.

Barton SE, Munday PE, Kinghorn GR, Van Der Meijden WI, Stolz E, Notowicz A, et al. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscamet); double blind, placebo controlled, multicentre study, Genitourin Med. 1986;62:247-50.

Vynograd N, Vynograd I, Sosnowski Z. A comparative multi-centre study of the efficacy of propolis, acyclovir and placebo in the treatment of genital herpes (HSV). Phytomedicine. 2000;7(1):1-6.

Abonyi D, Adikwu MU, Esimone CO & Ibezim, EC. Plants as sources of antiviral agents. African J Biotech. 2009;8:3989-94.